But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
AZD0120’s first pivotal trial will test settings as early as the second line.
Two new pivotal Chinese first-line trials have started in lung cancer.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company will start a phase 2/3 trial of PF-08634404 in March.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
